Novartis Gets Swiss Approval For First Malaria Drug For Babies

benzinga.com/news/health-care/25/07/46292859/novartis-gets-swiss-approval-for-first-malaria-drug-for-babies

Swissmedic, the Swiss Agency for Therapeutic Products, approved Novartis AG’s (NYSE:NVS) Coartem (artemether-lumefantrine) Baby on Tuesday. This marks the first malaria medicine specifically approved for newborns and young infants.
The new treatment, also known as Riamet Baby in some…

This story appeared on benzinga.com, 2025-07-08 11:57:32.
The Entire Business World on a Single Page. Free to Use →